| Oct 24 |
Q3 2024 Boston Scientific Corp Earnings Call
|
| Oct 23 |
Boston Scientific Pauses Enrollment In Farapulse Study In Drug-Naive Patients With Irregular Heart Rhythm
|
| Oct 23 |
Boston Scientific Q3: Good Growth, But Not Good Enough To Justify Its P/E Ratio
|
| Oct 23 |
Boston Scientific's Rockstar Segment Just Fumbled — And So Did Its Shares
|
| Oct 23 |
Wall Street Slumps For Third Straight Day As Investor Sentiment Fades, Dollar Strength Resumes, Boeing Disappoints: What's Driving Markets Wednesday?
|
| Oct 23 |
Boston Scientific Profit Falls Even as Demand for Its Heart Products Surges
|
| Oct 23 |
Boston Scientific Raises Full-Year Guidance After Third-Quarter Beat
|
| Oct 23 |
BSX Q3 Earnings Top, Stock Down in Premarket as Operating Margin Falls
|
| Oct 23 |
Growing Biosimilars Business Supports ABT Stock, Macro Issues Hurt
|
| Oct 23 |
Boston Scientific Faces Trial Setback, But This Game-Changing Growth Surge Could Ignite the Stock
|
